Celiac Disease Clinical Trial
Official title:
Protocol for Correlating Enteropathic Severity and Small Intestinal CYP3A4 Activity in Patients With Celiac Disease
The small bowel biopsy is the cornerstone of for the diagnosis of celiac disease. In
addition to being the gold standard for the initial diagnosis of celiac disease, periodic
biopsies are also recommended on an ongoing basis for this life-long disease. However,
biopsy evaluation is invasive and expensive. Therefore, there is a need for simple,
non-invasive tests that can be performed on celiac patients with subclinical disease.
The present study is based on the hypothesis that the expression and activity of cytochrome
P450 CYP3A4 in the small intestinal mucosa is a sensitive measure of enteropathy. Therefore
small intestinal CYP3A4 activity will be markedly different in celiac disease patients with
active disease as compared to patients in remission. Small intestinal CYP3A4 activity will
be measured in three ways:
(i) Cmax of oral simvastatin, a widely used drug that is predominantly metabolized by small
intestinal CYP3A4; (ii) AUC of oral simvastatin; and (iii) Measurement of CYP3A4 activity in
two small bowel biopsies.
The proposed study is based on the hypothesis that the expression and activity of cytochrome
P450 CYP3A4 in the small intestinal mucosa is a sensitive measure of enteropathy. Therefore
small intestinal CYP3A4 activity will be markedly different in celiac disease patients with
active disease as compared to patients in remission. Small intestinal CYP3A4 activity will
be measured in three ways:
(iv) Cmax of oral simvastatin, a widely used medication that is predominantly metabolized by
small intestinal CYP3A4; (v) AUC of oral simvastatin; and (vi) Measurement of CYP3A4
activity in two small bowel biopsies.
Objectives Primary Objectives
- To test the hypothesis that a positive correlation exists between villus height: crypt
depth (Vh:Cd) ratio and the specific activity of CYP3A4 in small intestinal biopsy
samples derived from subjects with celiac disease.
- To test the hypothesis that an inverse correlation exists between small intestinal
villus height: crypt depth (Vh:Cd) ratio and the maximum serum concentration (Cmax) of
simvastatin (20 mg, orally dosed after fasting) in subjects with celiac disease
Secondary Objectives:
- To test the hypothesis that an inverse correlation exists between small intestinal
villus height: crypt depth (Vh:Cd) ratio and the serum area-under-the-curve (AUC) of
simvastatin (20 mg, orally dosed after fasting) in subjects with celiac disease
- To test the hypothesis that a positive correlation exists between small intestinal
villus height : crypt depth (Vh:Cd) ratio and the relative expression level of CYP3A4
protein in subjects with celiac disease.
- To test the hypothesis that an inverse correlation exists between small intestinal
villus height : crypt depth (Vh:Cd) ratio and the concentration of simvastatin (20 mg,
orally dosed after fasting) in a 6-hour urine collection from subjects with celiac
disease.
- To test the hypothesis that a positive correlation exists between villus height : crypt
depth (Vh:Cd) ratio and the specific activity of CYP3A4 in small intestinal biopsy
samples derived from subjects with celiac disease who have followed a gluten-free diet
for > 1 year.
- To test the hypothesis that an inverse correlation exists between small intestinal
villus height: crypt depth (Vh:Cd) ratio and the maximum serum concentration (Cmax) of
simvastatin (20 mg, orally dosed after fasting) in subjects with celiac disease who
have followed a gluten-free diet for > 1 year.
- To test the hypothesis that an inverse correlation exists between small intestinal
villus height: crypt depth (Vh:Cd) ratio and the serum area-under-the-curve (AUC) of
simvastatin (20 mg, orally dosed after fasting) in subjects with celiac disease who
have followed a gluten-free diet for > 1 year.
- To test the hypothesis that a positive correlation exists between serum
anti-transglutaminase antibody levels and the specific activity of CYP3A4 in small
intestinal biopsy samples derived from subjects with celiac disease.
- To test the hypothesis that a positive correlation exists between the average daily
consumption of dietary gluten and the specific activity of CYP3A4 in small intestinal
biopsy samples derived from subjects with celiac disease.
;
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04349904 -
Near-Focus NBI Classification of Villous Atrophy in Suspected Coeliac Disease: International Development and Validation
|
||
| Recruiting |
NCT05581628 -
FREQUENCY OF FIBROMYALGIA IN PATIENTS WITH CELIAC DISEASE
|
||
| Completed |
NCT04593251 -
Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis
|
Phase 1 | |
| Completed |
NCT05810441 -
Intestinal Transglutaminase Antibodies in Celiac Disease Diagnosis
|
||
| Recruiting |
NCT05555446 -
Bovine Colostrum to Prevent Absorption of Gluten
|
Early Phase 1 | |
| Completed |
NCT02754609 -
Hookworm Therapy for Coeliac Disease
|
Phase 1 | |
| Terminated |
NCT01902368 -
Celiac Disease Screening
|
N/A | |
| Completed |
NCT02312349 -
Assessment of Gluten-Free Availability in Elaborated Food Stores in Three Neighbourhoods of Buenos Aires City
|
||
| Completed |
NCT02472704 -
Lymphocytic Enteritis and Suspected Coeliac Disease: Gluten vs Placebo
|
N/A | |
| Completed |
NCT01172665 -
Celiac Disease Database
|
||
| Completed |
NCT01100099 -
HLA-DQ2-gliadin Tetramer for Diagnosis of Celiac Disease
|
Phase 2/Phase 3 | |
| Completed |
NCT00639444 -
Risk of Celiac Disease and Age at Gluten Introduction
|
N/A | |
| Active, not recruiting |
NCT05425446 -
Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients
|
Phase 1 | |
| Enrolling by invitation |
NCT02202681 -
Imaging the Duodenum Using an Optical Frequency Domain Imaging OFDI Capsule
|
N/A | |
| Completed |
NCT00362856 -
Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects
|
Phase 2 | |
| Terminated |
NCT03866538 -
Budesonide in Patients With Immune Mediated Enteropathies
|
Phase 4 | |
| Recruiting |
NCT05135923 -
Glutenfree, Gut Microbiota and Metabolic Regulation
|
N/A | |
| Completed |
NCT05052164 -
Improvement Of Physical And Physiological Parameters In Menopausal Or Post-Menopausal Celiac Women
|
N/A | |
| Completed |
NCT03775499 -
Probiotic BL NCC 2705 and Gluten Sensitivity
|
N/A | |
| Completed |
NCT03707730 -
A Randomized, Double-Blind, Placebo Controlled, Crossover Trial to Evaluate Safety and Efficacy of AGY in Celiac Disease
|
Phase 2 |